Oslo, Norway, January 22, 2025 - Lytix Biopharma's licensing partner, Verrica
Pharmaceuticals, has presented clinical data on Lytix lead drug candidate,
LTX-315, at the 2025 Winter Clinical Dermatology Conference held January 17-19
in Miami, Florida. The results support a potential change in the treatment
paradigm for patients with basal cell carcinoma. 

The three posters presented by Verrica at the conference highlighted positive
clinical data from Part 2 of the Phase 2 study of LTX-315 (named VP-315 by
Verrica), a novel oncolytic peptide therapy for the treatment of basal cell
carcinoma (BCC). These presentations are important for Lytix, demonstrating the
significant progress being made in the development of LTX-315. 

BCC is the most common cancer type globally with more than 3.6 million new cases
in the US alone, each year. 

Highlights from the conference presentations:
Calculated Objective Response Rate (ORR): Verrica reported a calculated ORR of
97% based on post-hoc analysis. This ORR reflects the percentage of study
subjects who achieved at least a 30% tumor reduction along with partial or
complete response, without disease progression.

Efficacy and safety data: Additional posters featured data on the safety,
tolerability, and antitumor efficacy of LTX-315. The study demonstrated a
favorable safety profile, with no treatment-related serious adverse events and
only mild to moderate treatment-related adverse events.

"We are very pleased with Verrica's presentation of the LTX-315 data at the
Winter Clinical Dermatology Conference. These positive results reinforce the
potential of LTX-315 to transform the treatment paradigm for basal cell
carcinoma and highlight the strength of our oncolytic peptide technology," said
Øystein Rekdal, CEO of Lytix Biopharma.

Advancement toward regulatory discussions
Verrica plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug
Administration (FDA) in the first half of 2025 to determine the next steps for
the development of LTX-315 for BCC treatment. Genomic and T-cell immune response
data are expected in the first quarter of 2025.

 "The response rate of 97% and the promising safety and efficacy data underline
the potential for LTX-315 to provide a much-needed non-surgical treatment option
for BCC patients worldwide", adds Rekdal. 

Verrica believes that LTX-315 could serve as a potential first-line therapy for
both primary and neoadjuvant settings, offering an alternative to invasive
surgical treatments. Lytix shares this vision and remains committed to
supporting the advancement of LTX-315 as it moves toward Phase III development
and broader clinical application.

Read the full press release from Verrica here: 
https://verrica.com/press_release/verrica-pharmaceuticals-announces-presentation
-of-three-posters-featuring-positive-preliminary-topline-results-of-vp-315-for-t
he-treatment-of-basal-cell-carcinoma-at-the-2025-winter-clinical-dermatolo/ 

For any questions, please contact: 
Gjest Breistein, CFO 
gjest.breistein@lytixbiopharma.com 
+47 952 60 512 
 
About Lytix Biopharma 
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.